Suchergebnisse - "O'Connor, Owen A"

PubPharm (31)

1

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

enthalten in: Blood | 2021

von Hamadani, M. | Radford, J. | Carlo-Stella, C. | +14

CommentIn: Blood. 2021 May 13;137(19):2568-2570. - PMID 33983420

2

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL : a multicenter phase 2 study

enthalten in: Blood | 2021

von Falchi, L. | Ma, H. | Klein, S. | +18

ErratumIn: Blood. 2022 Mar 10;139(10):1600. - PMID 35267001

3

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Kahl, B. | Hamadani, M. | Radford, J. | +12

4

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL : a multicenter phase 1 study

enthalten in: Blood | 2019

von O'Connor, O. | Falchi, L. | Lue, J. | +22

CommentIn: Blood. 2019 Oct 24;134(17):1364-1365. - PMID 31698426

5

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von O'Connor, O. | Özcan, M. | Jacobsen, E. | +27

6

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Horwitz, S. | O'Connor, O. | Pro, B. | +129

CommentIn: Lancet. 2019 Jan 19;393(10168):201-202. - PMID 30663580

7

Brentuximab vedotin plus bendamustine : a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

enthalten in: Blood | 2018

von LaCasce, A. | Bociek, R. | Sawas, A. | +14

CommentIn: Blood. 2018 Jul 5;132(1):1-3. - PMID 29976776

8

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma : an international, multicentre, single-arm, phase 1-2 trial

enthalten in: The Lancet. Oncology | 2018

von O'Connor, O. | Lue, J. | Sawas, A. | +19

CommentIn: Lancet Oncol. 2018 Feb;19(2):162-163. - PMID 29276023

9

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

enthalten in: Leukemia & lymphoma | 2017

von Bartlett, N. | Smith, M. | Siddiqi, T. | +13

CommentIn: Leuk Lymphoma. 2017 Jul;58(7):1524-1525. - PMID 28278730

10

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

enthalten in: British journal of haematology | 2017

von Sawas, A. | Farber, C. | Schreeder, M. | +10